# Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

> **NCT05599932** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Siremadlin

## Key facts

- **NCT ID:** NCT05599932
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-02
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-09-18
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599932, "Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05599932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*